Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - céfuroxime axétil 300,72 mg - eq. céfuroxime 250 mg - comprimé pelliculé - 250 mg - céfuroxime axétil 300.72 mg - cefuroxime

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - céfuroxime axétil 601,44 mg - eq. céfuroxime 500 mg - comprimé pelliculé - 500 mg - céfuroxime axétil 601.44 mg - cefuroxime

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - céfuroxime axétil 60,14 mg/ml - eq. céfuroxime 50 mg/ml - granulés pour suspension buvable - 250 mg/5 ml - céfuroxime axétil 60.14 mg/ml - cefuroxime

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Union européenne - français - EMA (European Medicines Agency)

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Union européenne - français - EMA (European Medicines Agency)

teva b.v. - chlorhydrate de doxorubicine - néoplasmes du sein - agents antinéoplasiques - myocet liposomale, en association avec le cyclophosphamide, est indiqué pour le traitement de première ligne du cancer du sein métastatique chez les femmes adultes.

Union européenne - français - EMA (European Medicines Agency)

baxter holding b.v. - chlorhydrate de doxorubicine - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - agents antinéoplasiques - caelyx liposomale pégylée est indiqué:en tant que monothérapie pour les patients atteints de cancer du sein métastatique, où il y a une augmentation du risque cardiaque;pour le traitement du cancer avancé de l'ovaire chez les femmes qui ont échoué une première ligne de chimiothérapie à base de platine régime;en association avec le bortézomib pour le traitement de la progressive du myélome multiple chez les patients qui ont reçu au moins un traitement antérieur et qui ont déjà fait l'objet ou qui sont impropres à la greffe de moelle osseuse;pour le traitement du sida liés au sarcome de kaposi (ks) dans les patients avec un faible taux de cd4 (.

Union européenne - français - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - chlorhydrate de doxorubicine - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agents antinéoplasiques - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Union européenne - français - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infections des voies respiratoires - les antibactériens à usage systémique, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Union européenne - français - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - néoplasmes pancréatiques - agents antinéoplasiques - traitement de l’adénocarcinome métastatique du pancréas, en combinaison avec 5 fluoro-uracile (5-fu) et la leucovorine (lv), chez les patients adultes qui ont progressé suite gemcitabine fondée thérapie.